Ning Wang*1, Tingting Zhang†1
Oncology Research, Vol.26, No.7, pp. 1005-1014, 2018, DOI:10.3727/096504017X15144755633680
Abstract Personalized treatment targeting the epidermal growth factor receptor (EGFR) may be a promising new
treatment of non-small cell lung cancer (NSCLC). Gefitinib, a tyrosine kinase inhibitor, is the first drug for
NSCLC, which unfortunately easily leads to drug resistance. Our study aimed to explore the functional role of
microRNA (miR)-135 in the sensitivity to gefitinib of NSCLC cells. Expression of miR-135 in normal cells
and NSCLC cells was assessed, followed by the effects of abnormally expressed miR-135 on cell viability,
migration, invasion, apoptosis, sensitivity to gefitinib, and the expression levels of adhesion molecules and
programmed… More >
Login
Register
